Hematologic Oncology Treatment Center

More than 100 clinical trials are currently underway in the Center for Hematologic Oncology. The combined resources of our partner organizations within Dana-Farber/Harvard Cancer Center make us the largest cancer research center in the nation.

Leukemia, myelodysplasia, myelodysplastic syndromes, and myeloproliferative neoplasms research

The leukemia team works to develop more effective, less toxic treatments for acute leukemia and related disorders, including myelodysplastic syndromes, chronic myeloid leukemia, and myeloproliferative neoplasms.

Our clinical research focuses on understanding how leukemia cells develop and creating new ways to block their growth. We are also taking the innovative step of treating adult acute lymphoblastic leukemia (ALL) patients using treatments that have proved successful in pediatric patients.

Lymphoma research

Our lymphoma research focuses on translating laboratory findings into less toxic treatments. We are committed to investigating and understanding the genetic pathways that enable lymphoma cells to survive and manipulating them with targeted therapies to improve outcomes.

Our research program features a variety of trials specifically for chronic lymphocytic leukemia (CLL) patients, focusing on familial CLL, genomic studies and testing of novel therapies.

Multiple myeloma research

The Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics encompasses a large team of laboratory-based and clinical scientists investigating more effective therapies for multiple myelomas. Promising new therapies are rooted in a "bench-to-bedside" approach, where laboratory discoveries are rapidly translated into the clinical setting as part of treatment.

Waldenström's macroglobulinemia research

The main goal of clinical research at the Bing Center for Waldenström's Macroglobulinemia is to take laboratory discoveries to the clinic, where they can benefit Waldenström's patients.

Trials include studies aimed at improving outcomes of patients undergoing biological therapies that attempt to destroy the tumor cells directly; evaluating supportive therapies; and examining the genetic basis of the disease.